Future Science Group
SUPPLEMENTAL Figures.docx (71.7 kB)

Supplementary Figures_FON-2021-1336

Download (71.7 kB)
posted on 2022-03-21, 10:11 authored by Figshare Future Science GroupFigshare Future Science Group, Lei ZhangLei Zhang, Yijiao Qian, Jinnan Li, Chenwei Cui, Lu ChenLu Chen, Shuli Qu, Shun Lu
Appendix Figure 1: Flowchart of study selection
Appendix Figure 2: Quality assessment for included trials
Appendix Table 4: PRISMA checklist

Indirect comparison of sintilimab and other PD-(L)1 for first-line treatment of non-squamous non-small-cell lung cancer


Objective: To evaluate sintilimab compared with other PD-(L)1 inhibitors in combination with platinum-based doublet chemotherapy as the first-line treatment of non-squamous non-small-cell lung cancer (nsqNSCLC).

Methods: A frequentist meta-analysis was used to compare outcomes including progression-free survival (PFS), OS (overall survival), objective response rate, time to response and safety profile.

Results: Sintilimab-combination arm had a comparable PFS with that of pembrolizumab-combination arm (HR=1.00, 95% CI: 0.71, 1.41), atezolizumab-combination arm (HR=0.81, 95% CI: 0.59, 1.10), tislelizumab-combination arm (HR= 0.75, 95% CI: 0.48, 1.16), camrelizumab-combination arm (HR=0.80, 95% CI: 0.54, 1.20) and nivolumab-combination arm (HR=0.72, 95% CI: 0.51, 1.02). Any grade or grade ≥3 adverse event was comparable between PD-(L)1 inhibitors.

Conclusion: Sintilimab showed comparable efficacy and safety profile when comparing with other PD-(L)1 inhibitors combined with PT-DC as the first-line treatment of locally advanced or metastatic nsqNSCLC.


Eli Lilly